Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL
Adam B. Olshen(University of California, San Francisco), Catherine C. Park(University of California, San Francisco), David C. Newitt(American College of Radiology), Laura van ‘t Veer, Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Julia Wulfkuhle(University of California, San Francisco), Nola M. Hylton(University of California, San Francisco), Ella F. Jones(University of California, San Francisco), Rosa I. Gallagher(George Mason University), Christina Yau(Hospital Authority), Denise M. Wolf, Laura J. Esserman(University of California, San Francisco), Lisa Singer(University of California, San Francisco)
Cited by 6
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k